Enterprise Therapeutics doses first person with cystic fibrosis in Phase 2 trial for novel therapy ETD001

FHS
July 24, 2024
10:28 am

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of those suffering from respiratory disease, today announced dosing of the first person with cystic fibrosis (pwCF) in its Phase 2a trial of ETD001.

Alzheimer’s total prevalent cases to reach 22.51 million in 8MM in 2033 – Pharmaceutical Technology

Women accounted for approximately 73% of total prevalent Alzheimer’s cases in 2023. Credit: Antonio Marca / Shutterstock. Estimates by data analytics company GlobalData suggest that

January 10, 2025

Digital DNA melting analysis can be a faster and more reliable tool for pathogen detection

A new analysis method can detect pathogens in blood samples faster and more accurately than blood cultures, which are the current state of the art

February 21, 2024

Researchers develop platform allowing mass-scale production of SARS-CoV-2 mRNA lipid nanoparticle vaccines

Researchers presented a scalable lipid nanoparticle production (SCALAR) platform to develop SARS-CoV-2 mRNA lipid nanoparticle vaccines.

August 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.